Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Despite having a lower risk of hospitalization, cardiovascular events, and mortality, patients with IgAN and FSGS had a higher risk of CKD progression.

IgAN, FSGS Linked to Greater Kidney Replacement Therapy Risk Than Common CKD Etiologies

In the final segment of this episode, the discussion focuses on next steps for the PARASOL Initiative and its potential to transform FSGS drug development.

Kidney Compass: Future of PARASOL and FSGS Management

In part 2 of 4 from this episode, the discussion focuses on the groundbreaking work of the RADAR Registry and the PARASOL Initiative.

Kidney Compass: PARASOL Background and FSGS Landscape

In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir.

Kidney Compass: Introducing the PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir

This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.

Kidney Compass: The PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir

Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.

Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH

Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population. 

Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research 

Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.

Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS

Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.

Ladan Zand, MD: Obinutuzumab a Promising Option for Refractory, Primary FSGS

A posthoc analysis of the DUPLEX trial suggests patients with genetic FSGS may experience a more pronounced and sustained antiproteinuric response with sparsentan.

DUPLEX: Sparsentan Could Offer Greater Benefit in Genetic FSGS

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Focal Segmental Glomerulosclerosis